ClinicalTrials.gg
RecruitingNCT07734064DEVOTEUpdated Oct 28, 2026

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

A Phase 1 interventional study of ASP2020 in Stargardt Disease, Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy, sponsored by Astellas Institute for Regenerative Medicine. Recruiting at 4 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Astellas Institute for Regenerative Medicine (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 23, 2026Start date moved1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
14th of 26
30 · median 41
Started
2026
with 5 others
Phase 1
5 of 42
3 open now
Primary completion
2029-09
later than 17 of 24 live
Registered
42nd of 42
by date
Lead sponsor
3 of 42
Astellas Institute for Regenerative Medicine

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 14th largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 17 of the 24 other live ones, and was the 42nd registered.

Stargardt Disease

67 studies on the registry are indexed under Stargardt Disease; 26 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Stargardt Disease studies recruiting now, 14 (61%) set no upper age limit and 7 (30%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to loss of central vision, which can make it harder to read, recognize faces or see fine details. What's seen out of the corner of the eye (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically begins in childhood or teenage years but may also develop in adulthood. As well as STGD, there are other macular dystrophies that look very similar to STGD and are called STGD-like macular dystrophies. These are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies.

This is an early development study of ASP2020 in adults, teenagers, and children with STGD-type macular dystrophies. ASP2020 are human stem cells which have been changed into cells found in the macula. In this study ASP2020 will be given to people for the first time. The main aim of the study is to check the safety of ASP2020 and how well people tolerate it. Other aims are to learn if people have an immune reaction to ASP2020, and if there are signs that the stem cells replace damaged cells in the retina, and vision improves for people with STGD-type macular dystrophies.

ASP2020 will be given as a single injection into the eye, under the retina. This requires a surgical procedure where the person is put to sleep by a general anesthetic. At the end of surgery, a steroid will be injected into the eye to reduce any swelling.

The study has 2 parts. In Part 1, different small groups will receive a lower to higher dose of ASP2020. This is done to find a suitable dose to use in Part 2. The adults will receive the lower dose and higher dose before the teenagers. There will be a 6-month gap between the last adult receiving the lower dose of ASP2020 and the first teenager receiving the same lower dose. This will also happen for the last adult receiving the higher dose of ASP2020 and the first teenager receiving the higher dose of ASP2020. Any medical problems will be recorded for each dose in each group. Children will not receive ASP2020 in Part 1.

In Part 2, different groups of adults, teenagers and children will receive the most suitable dose of ASP2020 worked out from Part 1.

People will be in the study for about 1 year and they will visit the clinic several times. In both parts of the study, safety checks will be done at each visit, and the study doctors will continue to check for any medical problems throughout the study. Various eye tests and eye imaging will be done throughout the study. Blood tests will also be done at some of the visits during the study.

03

Conditions studied

  • Stargardt Disease
  • Stargardt Macular Dystrophy
  • Stargardt-like Macular Dystrophy

Keywords

  • Macular Dystrophies
  • Stargardt type
  • ABCA4 related STGD
  • STGD-like macular dystrophies
  • Safety
  • STGD
  • STGD-like
  • STGD-type
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented clinical diagnosis of macular dystrophy with a STGD-type clinical presentation and molecular confirmation, defined as either:

    • STGD: presence of biallelic (pathogenic or likely pathogenic) ABCA4 variants, or one definite disease-causing ABCA4 variant together with a typical phenotype consistent with STGD.
    • STGD-like macular dystrophy: presence of one or more pathogenic variants in a gene known to cause macular dystrophy, as appropriate for its expected inheritance mode.
  • Sufficiently clear ocular media and adequate pupillary dilation to allow for all imaging procedures.
  • Intraocular pressure (IOP) of ≤ 21 mmHg
  • Participant has a spherical equivalent refractive error between +8.00 D and -10.00 D.
  • BCVA ranging from 20/500 to 20/40 (equivalent to 15 to 70 ETDRS letters)

    • For participants in the > 20/80 to ≤ 20/40 BCVA range (moderate visual impairment [MVI]): presence of a visible definite or probable residual ellipsoid zone (EZ) on SD-OCT, and a total retinal SD-OCT central subfield thickness ≥ 150 micrometers (µm)
    • For participants in the ≥ 20/500 to ≤ 20/80 BCVA range (severe visual impairment): Presence of a residual ONL within the macular optical coherence tomography (OCT) scan area and Evidence of RPE disease/damage by means of SD-OCT (hypertransmission defect) and/or FAF imaging (questionably decreased autofluorescence/definitely decreased autofluorescence).

Exclusion criteria

Exclusion Criteria:

  • Participant has a known history of significant systemic disease that could impact ocular health or confound study assessments, based on medical history or prior clinical documentation.
  • Participant has an condition that requires treatment with immunomodulatory therapy and/or biologics that cause .
  • Participant has known diagnosis of diabetes mellitus with a documented (HbA1c) value ≥ 7% 3 months prior to screening and based on available medical records.
  • Participant has a history or evidence of severe cardiac disease, cardiovascular or cerebrovascular disease, including a history of stroke within 12 months prior to screening.
  • Participant has any complicating systemic disease or active .
  • Participant has a known history of any systemic or metabolic condition, or physical examination finding that may significantly affect ocular health or interfere with the interpretation of study assessments.
  • Participant has presence of another known or suspected molecular diagnosis of macular or retinal disease that could confound interpretation of study outcomes, indicate a second concomitant retinal condition, or suggest a different etiology for the macular disease.
  • Participant has macular atrophy due to any cause other than a genetically or clinically confirmed diagnosis of STGD or STGD-like macular dystrophy.
  • Participant has evidence or history of choroidal neovascularization.
  • Participant has diagnosis of any form of uncontrolled glaucoma (for high-tension glaucoma IOP > 25 mmHg).
  • Participant has a history of -induced IOP elevation or known steroid responder status.
  • Participant has and/or is receiving treatment for thyroid eye disease.
  • Participant has diabetic retinopathy in excess of mild nonproliferative diabetic retinopathy
  • Participant has any other disease(s) affecting the optic nerve.
  • Participant has a history of anterior or posterior uveitis and/or presence of intraocular inflammation (trace anterior chamber cell or flare), or history of idiopathic or autoimmune-associated uveitis in either eye.
  • Participant has media opacities impeding the visualization of the fundus and/or the reliable performance of the visual function tests required by the protocol.
  • Participant has aphakia.
  • Participant has a clinically significant epiretinal membrane or evidence of clinically significant vitreomacular traction syndrome.
  • Participant has any other disorders which could interfere with or confound visual acuity and other ocular assessments, including OCT or FAF.
  • Participant has history of any of the following procedures: posterior vitrectomy, retinal detachment surgery, glaucoma filtering surgery, glaucoma drainage device implantation, selective laser trabeculoplasty, full-thickness or partial- thickness corneal transplant.
  • Participant has had any intraocular surgery within 3 months of screening.
  • Participant has a history of intraocular metallic foreign bodies.
  • Participant has received any treatment including gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or any prior intravitreal treatment for any indication in either eye that may be considered to potentially interfere with the study participation or its conduct.
  • Participant has received within 1 month prior to screening or is receiving concomitant treatment with any ocular or systemic medication known to be toxic to the lens, retina, or optic nerve.
  • Participant has received any therapy within 3 months prior to screening.
  • Participant has any condition, which makes the participant unsuitable for study participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Part 1 Dose Escalation: Adult - Low Dose

    Adult participants will receive a single low dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

    Drug: ASP2020

  • Experimental
    Part 1 Dose Escalation: Adult - High Dose

    Adult participants will receive a single high dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

    Drug: ASP2020

  • Experimental
    Part 1 Dose Escalation: Adolescent - Low Dose

    Adolescent participants will receive single low dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

    Drug: ASP2020

  • Experimental
    Part 1 Dose Escalation: Adolescent - High Dose

    Adolescent participants will receive single high dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

    Drug: ASP2020

  • Experimental
    Part 2 Dose Expansion: Adult with macular dystrophies

    Adult participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

    Drug: ASP2020

  • Experimental
    Part 2 Dose Expansion: Pediatric with macular dystrophies

    Pediatric participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

    Drug: ASP2020

Interventions

  • DrugASP2020

    Subretinal Injection

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are defined as an AE observed after administration of ASP2020 or pre-existing AE that worsen in severity or frequency following administration of ASP2020.

    Time frame: Up to 52 weeks

  2. Number of participants with serious adverse events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important events.

    Time frame: Up to 52 weeks

  3. Number of participants with adverse events of special interest (AESIs)

    AESIs include, but are not limited to, the following: * Ectopic, excessive, or aberrant cell growth of ASP2020, including proliferative changes * Immune-mediated reactions, including unexpected or clinically significant inflammatory responses * Any new diagnosis of malignancy * Any clinically significant AEs possibly or definitely related to ASP2020 * Clinically significant AEs related to the surgical administration procedure

    Time frame: Up to 52 weeks

  4. Number of participants with greater than or equal to 15 letter loss in best corrected visual acuity (BCVA) from baseline

    BCVA will be measured from the Early Treatment of Diabetic Retinopathy Study (ETDRS) letters chart.

    Time frame: Up to 52 weeks

  5. Number of participants with significant changes in vital signs from baseline

    Number of participants with significant changes in vital signs from baseline will be reported.

    Time frame: Up to 52 weeks

  6. Number of participants with significant changes in laboratory values from baseline

    Number of participants with significant changes in laboratory values from baseline will be reported.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Change from baseline in BCVA

    BCVA will be measured from the ETDRS letters chart.

    Time frame: Baseline and week 26, 52 or Early Termination (ET) visit whichever occurs first

  2. Change from baseline in low luminance visual acuity (LLVA)

    LLVA will be measured from the ETDRS letters chart.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  3. Change from baseline in Minnesota Reading Acuity Chart (MNREAD) parameters

    MNREAD evaluates near reading acuity, reading speed and critical print size.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  4. Change from baseline in mesopic macular sensitivity

    Mean sensitivity, point-wise sensitivity (PWS), scotomatous/non-seen point count) will be measured by mesopic microperimetry.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  5. Change from baseline in central retinal thickness (CRT)

    CRT will be measured by spectral- domain optical coherence tomography (SD-OCT).

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  6. Change from baseline in total photoreceptor thickness (TPT)

    TPT will be measured by SD-OCT.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  7. Change from baseline in ellipsoid zone (EZ) integrity

    EZ integrity will be measured by SD- OCT.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  8. Change from baseline in outer nuclear layer (ONL)

    ONL will be measured by SD-OCT.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  9. Change from baseline in retinal pigment epithelium (RPE) integrity

    RPE structural integrity will be measured by SD-OCT.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  10. Change from baseline in questionably decreased autofluorescence (QDAF)

    QDAF will be measured with fundus autofluorescence (FAF).

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  11. Change from baseline in definitely decreased autofluorescence (DDAF)

    DDAF will be measured with FAF.

    Time frame: Baseline and week 26, 52 or ET visit whichever occurs first

  12. Change from baseline in anti-human leukocyte antigen (HLA) antibodies

    Anti-HLA antibodies will be measured from the serum samples.

    Time frame: Baseline and week 4, 12 and 52 or ET visit whichever occurs first

  13. Change from baseline in anti herpes simplex virus thymidine kinase (HSV- TK) antibodies

    Anti HSV-TK antibodies will be measured from the serum samples.

    Time frame: Baseline and week 4, 12 and 52 or ET visit whichever occurs first

  14. Change from baseline in cytokines

    Cytokines will be measured from the serum samples.

    Time frame: Baseline and week 1, 4, 12 and 52 or ET visit whichever occurs first

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 29, 2026
StartActual
Aug 14, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Deep Blue Retina · Southaven, United States
Oct 23, 2026
Start date
Aug 10, 2026→Aug 14, 2026
Oct 23, 2026
Show all 2 updates
  1. Oct 28, 2026
    Minor edits only
    + 1 other change: identifiers
  2. Oct 23, 2026
    1 site added
    Show site
    • Deep Blue Retina · Southaven, United States
    Start date Aug 10, 2026→Aug 14, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07734064
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Aug 14, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Astellas Institute for Regenerative Medicine
Contact
Astellas.registration@astellas.com
800-888-7704
Medical Lead
study director · Astellas Institute for Regenerative Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion